Oxybutynin

For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.

Active substance: Oxybutynin

Examples of brand names: Dridase [DE]

ATC code: G04BD04

Main use (for orientation): Overactive bladder

Documented research summary

A CBD ureteroscopy RCT in 90 people includes oxybutynin as prescribed standard co-medication. No isolated oxybutynin pharmacokinetic/interaction analysis. The atomoxetine–dronabinol study mentions oxybutynin only as a previous treatment approach.

Uncertainties and limitations

Documented individual title/abstract review with selected relevant full texts; not an exhaustive worldwide systematic review and no independent human professional approval. Missing data do not establish safety. All 28 cannabinoids define the search scope, not 28 clinically studied pairs per active substance.

Separately recorded findings

1 separately recorded finding. Each statement applies to its documented study context.

CBD – insufficient data

Finding ID: B0464

Type of result: No isolated investigation of the pair

Observation: CBD showed no additional analgesic benefit in the postoperative experiment; this does not answer an individual medicine-interaction question.

Mechanism: No individual effect of the pair investigated; standard accompanying treatment in both groups.

Study type: Randomised CBD experiment with non-isolated co-medication

Context studied: 90 people after ureteroscopy; CBD 20 mg daily for three days, several accompanying medicines including tamsulosin/oxybutynin.

Clinical interpretation: No isolated investigation of the pair; clinical relevance as a medicine–cannabinoid interaction cannot be determined.

Limitations and uncertainties: No pair-specific safety or pharmacokinetic analysis; do not use a null finding as proof of no interaction.

Original sources for this finding: Effect of Cannabidiol Oil on Post-ureteroscopy Pain for Urinary Calculi: A Randomized, Double-blind, Placebo-controlled Trial. [VF_P_36891837]

References and access status

[VF_L_D0365] OXYBUTYNIN CHLORIDE EXTENDED RELEASE (OXYBUTYNIN CHLORIDE) TABLET, EXTENDED RELEASE [AMERICAN HEALTH PACKAGING]

Original source / bibliographic reference

Authors: Marketing authorisation holder; official product information via DailyMed

Year: 2026

Source type: Official medicine information; relevant identity, PK, PD and DDI sections read individually

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

[VF_P_36891837] Effect of Cannabidiol Oil on Post-ureteroscopy Pain for Urinary Calculi: A Randomized, Double-blind, Placebo-controlled Trial.

Original source / bibliographic reference

Authors: Narang G, Moore J, Wymer K, Chang YH, Lim E, Adeleye O, Humphreys MR, Stern KL.

Year: 2023

Source type: Scientific publication; precise study type and suitability described in the finding or individual review

DOI: 10.1097/ju.0000000000003139

PMID: 36891837

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

DOI – publisher access (access restrictions may apply)

Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.

Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility